Lanerkitug

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Antibody
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Antibody
www.ebi.ac.uk
Drug name
Lanerkitug
www.ebi.ac.uk

  • bay 3375968
  • BAY 3375968
  • BAY 3375968 [WHO-DD]
  • bay 3375968 who dd
  • BAY-3375968
  • bay3375968
  • h gamma1 heavy chain homo sapiens 1 452 vh homo sapiens ighv3 23 01 92 9 ighd ighj4 01 93 3 8 8 15 26 33 51 58 97 111 1 122 homo sapiens ighg1 01 100 g1m17 1 ch1 k120 ch3 d12 l14 ch1 k120 219 123 220 hinge 1 15 221 235 ch2 236 345 ch3 d12 361 l14 363 346 450 chs 451 452 123 452 225 216 disulfide with l lambda2 light chain homo sapiens 1 217 v lambda homo sapiens iglv1 47 02 89 9 iglj3 02 100 cdr imgt 9 3 11 26 34 52 54 91 101 1 111 homo sapiens iglc2 01 100 112 217 dimer 231 231 234 234 bisdisulfide produced in chinese hamster ovary cho cells derived from cho k1 cell line lacking the glutamine synthetase gs ko gene and co expressing the rmd enzyme gdp 6 deoxy d lyxo 4 hexulose reductase glycoform alfa
  • H-gamma1 heavy chain Homo sapiens (1-452) [VH(Homo sapiens IGHV3-23*01 (92.9%) -(IGHD) -IGHJ4*01 (93.3%)) [8.8.15] (26-33.51-58.97-111) (1-122) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (219) (123-220), hinge 1-15 (221-235), CH2 (236-345), CH3 D12 (361), L14 (363) (346-450), CHS (451-452)) (123-452)], (225-216')-disulfide with L-lambda2 light chain Homo sapiens (1'-217') [V-LAMBDA (Homo sapiens IGLV1-47*02 (89.9%) -IGLJ3*02 (100%), CDR-IMGT [9.3.11](26'-34'.52'-54'.91'-101')) (1'-111') -Homo sapiens IGLC2*01 (100%) (112'-217')]; dimer (231-231'':234-234'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from CHO-K1 cell line, lacking the glutamine synthetase (GS-KO) gene, and co-expressing the RMD enzyme (GDP-6-deoxy-D-lyxo-4-hexulose reductase), glycoform alfa
  • immunoglobulin g1 anti human cc chemokine receptor ccr8 human monoclonal bay 3375968 γ1 chain disulfide with human monoclonal bay 3375968 λ chain dimer
  • immunoglobulin g1 lambda2 anti homo sapiens ccr8 c c motif chemokine receptor 8 ckr l1 cdw198 homo sapiens monoclonal antibody
  • immunoglobulin G1-lambda2, anti-[Homo sapiens CCR8 (C-C motif chemokine receptor 8, CKR-L1, CDw198)], Homo sapiens monoclonal antibody
  • Immunoglobulin G1, anti-(human CC chemokine receptor CCR8) (human monoclonal BAY 3375968 γ1-chain), disulfide with human monoclonal BAY 3375968 λ-chain, dimer
  • lanerkitug
  • Lanerkitug
  • lanerkitug [INN]
  • LANERKITUG [USAN]
  • lanerkitug inn
  • lanerkitug usan

CAS registry numbers
  • 2839417-54-6
ChEMBL ID
CHEMBL6068127
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • DNV66ACK7K

First in class
No
Orphan designation
No

Investigated indications

  • Condition
    Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000616
    Subject identifier
    D009369

  • Condition identifier
    EFO_0000616
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0001056
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0005070
  • Condition identifier
    MONDO_0005105
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0005627
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0007254
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0008903
    Highest recorded phase
    1

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Heavy chain
    Type
    Protein
    Sequence
    EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVSAINWNGGSTGYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGHHSGYDGRFFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  • Component
    Disulfide bridges
    Sequence
    22'-90' $ 22'''-90''' $ 22-96 $ 22''-96'' $ 139'-198' $ 139'''-198''' $ 149-205 $ 149''-205'' $ 225-216' $ 225''-216''' $ 231-231'' $ 234-234'' $ 266-326 $ 266''-326'' $ 372-430 $ 372''-430''
  • Component
    Light chain
    Type
    Protein
    Sequence
    QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYNVHWYQQLPGTAPKLLIYTNNRRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDASLSGWVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
  • Component
    Glycosylation sites (N)
    Sequence
    302 $ 302''

Related records

Trials (1)

In development for (6)